Home/Filings/4/0001790879-25-000007
4//SEC Filing

Topper James N 4

Accession 0001790879-25-000007

CIK 0001888012other

Filed

Sep 16, 8:00 PM ET

Accepted

Sep 17, 5:20 PM ET

Size

15.2 KB

Accession

0001790879-25-000007

Insider Transaction Report

Form 4
Period: 2025-09-17
Transactions
  • Disposition from Tender

    Common Stock

    2025-09-17$1.95/sh17,199$33,5380 total(indirect: By Patrick J. Heron)
  • Disposition from Tender

    Common Stock

    2025-09-17$1.95/sh8,535,337$16,643,9070 total(indirect: By Frazier Life Sciences X, L.P.)
FHMLS X, L.P.
10% Owner
Transactions
  • Disposition from Tender

    Common Stock

    2025-09-17$1.95/sh17,199$33,5380 total(indirect: By Patrick J. Heron)
  • Disposition from Tender

    Common Stock

    2025-09-17$1.95/sh8,535,337$16,643,9070 total(indirect: By Frazier Life Sciences X, L.P.)
Transactions
  • Disposition from Tender

    Common Stock

    2025-09-17$1.95/sh8,535,337$16,643,9070 total(indirect: By Frazier Life Sciences X, L.P.)
  • Disposition from Tender

    Common Stock

    2025-09-17$1.95/sh17,199$33,5380 total(indirect: By Patrick J. Heron)
Transactions
  • Disposition from Tender

    Common Stock

    2025-09-17$1.95/sh17,199$33,5380 total(indirect: By Patrick J. Heron)
  • Disposition from Tender

    Common Stock

    2025-09-17$1.95/sh8,535,337$16,643,9070 total(indirect: By Frazier Life Sciences X, L.P.)
Transactions
  • Disposition from Tender

    Common Stock

    2025-09-17$1.95/sh8,535,337$16,643,9070 total(indirect: By Frazier Life Sciences X, L.P.)
  • Disposition from Tender

    Common Stock

    2025-09-17$1.95/sh17,199$33,5380 total(indirect: By Patrick J. Heron)
Footnotes (3)
  • [F1]Reflects disposition of the Issuer's equity securities upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 4, 2025, by and among Issuer, XOMA Royalty Corporation ("Parent") and XRA 4 Corp., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on September 17, 2025. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each share of the Issuer's Common Stock, par value $0.0001 per share ("Shares"), issued and outstanding immediately prior to the Effective Time was converted automatically into the right to receive (i) $1.95 in cash, without interest plus (ii) one non-transferable contractual contingent value right per Share.
  • [F2]The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X,, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. James N. Topper and Patrick J. Heron are the sole managing members of FHMLS X, L.L.C. and share voting and investment power over the shares held by Frazier Life Sciences X, L.P. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
  • [F3]Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding restricted stock unit ("RSU") immediately vested in full and was canceled in exchange for the right receive (a) an amount in cash, without interest, equal to the product obtained by multiplying (x) the $1.95 by (y) the number of shares underlying such RSU at the Effective Time and (b) one CVR for each share underlying such RSU.

Issuer

HilleVax, Inc.

CIK 0001888012

Entity typeother

Related Parties

1
  • filerCIK 0001341382

Filing Metadata

Form type
4
Filed
Sep 16, 8:00 PM ET
Accepted
Sep 17, 5:20 PM ET
Size
15.2 KB